Search
for

    Glossary Gleason Score

    grading system for prostate cancer cell patterns' aggressiveness

    The Gleason Score is a grading system used to evaluate the aggressiveness of prostate cancer by examining the patterns of cancer cells in a biopsy sample. It ranges from 2 to 10, with higher scores indicating more aggressive and poorly differentiated tumors, which are more likely to spread. This score helps guide treatment decisions and predict patient outcomes.

    Related Terms

    Research 10 of 252

    1. 1449 PROSTATE CANCER PATIENTS WITH METABOLIC SYNDROME SHOWED LOW GRADE GLEASON SCORE WHEN DIAGNOSED ON BIOPSY The Journal of Urology · 2012
    2. S89 Clinical outcomes of high risk prostate adenocarcinoma (T3 and Gleason score ≥8) European Urology Supplements · 2009
    3. Gleason grading controversies: what the chemoprevention trials have taught us Canadian Urological Association Journal · 2013 · 4 citations
    4. Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial British Journal of Cancer · 2009 · 49 citations
    5. Differential expression of steroid 5α-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer Endocrine Related Cancer · 2010 · 30 citations
    6. Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers The Prostate · 2017 · 7 citations
    7. Finasteride: Middle-Age Cure-All for Alopecia and Benign Prostatic Hyperplasia?–Reply–I Mayo Clinic Proceedings · 2006 · 2 citations
    8. A Chance Finding of High Grade Prostate Cancer in a 35-Year-Old Male – A Case Report and Outcomes of Robotic Radical Prostatectomy in Young Men with Prostate Cancer Research and reports in urology · 2023
    9. Two cases of low-prostate-specific antigen localized prostate cancer incidentally detected by computed tomography Authorea (Authorea) · 2022
    10. Urological Oncology: Prostate Cancer The Journal of Urology · 2008
    All research results →

    Learn 1

    1. Dutasteride 5-alpha reductase inhibitor that blocks both enzyme types, a stronger DHT blocker than finasteride

    Community

    — no results

    Try a deeper search in community →